The Food and Drugs Board (FDB) has warned the public against patronising Mezol MF suspension and Brufpa Suspension, two pharmaceutical products currently being sold on the market, because they are sub-standard.
The Board has also directed all pharmacies and licensed chemical shops to immediately return the said products in their custody to either the FDB offices, the Pharmacy Council or the importers.
Mezol MF suspension contains Metronidazole and Furazolidone and treat bacterial or protozoan infections, while Brufpa Suspension is a pain-killer which contains Ibuprofen and Paracetamol.
A statement signed by B.K. Botwe, Deputy Chief Executive of the Board, said both products were manufactured by RHR Medicore Pharmaceuticals Ltd of India and imported by Hovid Pharmaceuticals Ltd, Ghana.
The statement advised the public against patronizing the products since their safety and quality could not be guaranteed.
"Anyone who patronizes them does so at his or her own risk," it said, adding, "The Board is however doing all in its power to ensure the complete withdrawal of the products from the market."